Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the
Alzheimer's disease (AD) continuum. Investigating populations with SCD is important for …

There is increasing evidence that subjective cognitive decline (SCD) in individuals with
unimpaired performance on cognitive tests may represent the first symptomatic …

As the field begins to test the concept of a" preclinical" stage of neurodegenerative disease,
when the pathophysiological process has begun in the brain, but clinical symptoms are not …

What can be expected in normal aging, and where does normal aging stop and pathological
neurodegeneration begin? With the slow progression of age-related dementias such as …

Importance Assessing the ability of Alzheimer disease neuroimaging markers to predict
short-term cognitive decline among clinically normal (CN) individuals is critical for upcoming …

Recent developments of PET amyloid ligands have made it possible to visualize the
presence of Aβ deposition in the brain of living participants and to assess the consequences …

Objective: Several lines of evidence suggest that pathologic changes underlying Alzheimer
disease (AD) begin years prior to the clinical expression of the disease, underscoring the …

More educated elders are less susceptible to age-related or pathological cognitive changes.
We aimed at providing a comprehensive contribution to the neural mechanism underlying …

Does accelerated cortical atrophy in aging, especially in areas vulnerable to early
Alzheimer's disease (AD), unequivocally signify neurodegenerative disease or can it be part …

Objective: To identify biological evidence for Alzheimer disease (AD) in individuals with
subjective memory impairment (SMI) and unimpaired cognitive performance and to …